English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 22 February 2021, 13:11 JST
Share:
    

Source: Eisai
Eisai Receives Corporate Philanthropy Award for Its Efforts to Realize Human Health Care (hhc) Philosophy

TOKYO, Feb 22, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received the 18th Corporate Philanthropy Award (FY 2020) of the Japan Philanthropic Association. The presentation ceremony was held on February 19, 2021 (Friday) at the GakushiKaikan (Chiyoda-ku, Tokyo).

Award ceremony (left: Ms. Yoko Takahashi, director, the Japan Philanthropic Association, right: Keigo Kato, executive director, Knowledge Creation Dept., Eisai)

The Corporate Philanthropy Award was founded in 2003 with the aim of commending companies for their activities for social contribution that organically and sustainably utilize their management resources (human resources, know-how, technology, information, etc.) in order to solve social issues, and of passing on a fair, warm and vibrant society to the next generation by broadly disseminating those social contribution activities to society.

The award was presented to Eisai for its corporate philosophy of human health care (hhc) and its activities to realize the hhc philosophy, evaluating "a corporate culture and purposeful activities where employees demonstrate their true value toward the realization of a society in which people can live happily."

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides, and Eisai calls this philosophy the "human health care (hhc)" philosophy, in one word. In 2005, Eisai stipulated this philosophy as one of its Articles of Incorporation with the support of its shareholders. As an initiative to embody this hhc philosophy, Eisai recommends all officers and employees of the Eisai Group, including outside directors, to spend 1% of their business hours with patients and to engage in "socialization" to know their emotions. In addition, for developing and emerging countries, Eisai has continuously provided a treatment for lymphatic filariasis, which is one of the neglected tropical disease (NTDs), free of charge to endemic counties through the World Health Organization (WHO). Furthermore, Eisai has adopted the tiered-pricing model for its innovative new drugs, which sets multiple tiered prices according to the patient's income level and the insurance coverage that patients could afford. Thus, we are promoting various efforts to improve access to pharmaceutical products.

Eisai will make continuous efforts, based on the hhc philosophy, to further contribute to increasing the benefits of patients and their families around the world.

Topic: Press release summary
Source: Eisai

Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Related News
2026年2月16日 15時00分 JST
エーザイ、新規オレキシン受容体作動薬 E2086 が日本において、ナルコレプシーを対象として、厚生労働省より希少疾病用医薬品に指定
Monday, 16 February 2026, 14:03 JST
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
Tuesday, 10 February 2026, 13:34 JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
Friday, 6 February 2026, 11:31 JST
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
Monday, 26 January 2026, 11:37 JST
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
More news >>
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575